Target intelligence / Profile preview

Cell-free DNA methylation pattern analysis

Molecular classification
Other (Bioanalytical target/process, not a molecule, receptor, or protein family)
01

Overview

Cell-free DNA methylation pattern analysis refers to methods by which the methylation profile of circulating, fragmented DNA found in bodily fluids is assessed as a noninvasive biomarker for disease detection, tissue-of-origin identification, and monitoring of biological processes. cfDNA methylation patterns reflect their tissue or cellular origin due to cell-type-specific DNA methylation signatures. Analysis of these patterns is increasingly used for the diagnosis and monitoring of cancers, noninvasive prenatal testing, and in transplantation medicine. Technologies range from bisulfite sequencing and methylation-sensitive enzyme digestion to advanced fragmentomic assays (such as FRAGMA), which can predict methylation from DNA fragmentation profiles[1][2][3][4][5][6]. Although not a biological target amenable to drug interaction, cfDNA methylation profiling is a powerful bioanalytical tool for precision diagnostics. Its main challenges include technical issues such as DNA degradation during sample processing and limited specificity of some assays[4][6].

Other names
cfDNA methylation profilingcfDNA methylome analysiscfDNA fragmentomics-based methylation analysisFRAGMA
02

Biological functions

Other (Detection and profiling of underlying biological processes such as apoptosis, cell death, tissue-of-origin analysis, epigenetic regulation)
03

Disease associations

Cancer (diagnosis, monitoring, tissue-of-origin detection)Inflammation (cfDNA may reflect tissue injury or inflammation)Prenatal diagnostics (noninvasive fetal assessment)Organ transplantation (monitoring tissue injury)
04

Safety considerations

Technical limitations (possible DNA degradation during bisulfite treatment; assay sensitivity/specificity for early disease detection or tissue-of-origin deconvolution)Lack of specificity for total cfDNA in some clinical contexts
05

Biomarkers

cfDNA methylation patterns (Cancer diagnosis and monitoring; tissue-of-origin biomarkers)Fragmentomic biomarkers (size distribution and cleavage patterns in cfDNA for disease status)

Beyond the preview

Go deeper on Cell-free DNA methylation pattern analysis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell-free DNA methylation pattern analysis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call